A first time report on the coocurrence of sarcoidosis and ALK(-) CD30(+) anaplastic large cell lymphoma that is highly responsive to brentuximab vedotin treatment

J Oncol Pharm Pract. 2019 Oct;25(7):1801-1805. doi: 10.1177/1078155219837331. Epub 2019 Mar 25.

Abstract

Sarcoidosis is known to be associated with higher incidence of solid tumors and hematological malignancies. ALK(-) CD30(+) anaplastic large cell lymphoma is a type of non-Hodgkin lymphoma showing poor prognosis, and seldom co-occurs with sarcoidosis. As this rare and highly mortal disease did not respond to classical chemotherapies and showed remission with brentuxumab vedontin treatment, we are presenting our first case reported from Turkey hoping to contribute to the literature.

Keywords: ALK(−) CD30(+) anaplastic large cell lymphoma; Sarcoidosis; brentuximab vedotin treatment.

Publication types

  • Case Reports

MeSH terms

  • Brentuximab Vedotin
  • Humans
  • Immunoconjugates / administration & dosage*
  • Ki-1 Antigen / metabolism
  • Lymphoma, Large-Cell, Anaplastic / drug therapy*
  • Male
  • Sarcoidosis / drug therapy*
  • Turkey
  • Young Adult

Substances

  • Immunoconjugates
  • Ki-1 Antigen
  • Brentuximab Vedotin